Form 4: Adverum Biotechnologies CEO Granted Stock Options

CEO Laurent Fischer received stock options for 200,000 shares of Adverum Biotechnologies stock on August 2, 2024.

Summary

• Laurent Fischer, CEO, President, and Director of Adverum Biotechnologies, was granted stock options on August 2, 2024.
• The options are for 200,000 shares of Adverum Biotechnologies common stock.
• The exercise price of the options is $7.15 per share.
• The options vest over three years, with one-third vesting on the first anniversary of August 2, 2024, and the remainder vesting monthly thereafter.
• The options expire on August 1, 2034.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, the grant can be viewed positively as it aligns management's interests with shareholders.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The size and vesting schedule of the grant are typical for a CEO of a company of Adverum's size and stage of development.
• Comparable companies such as REGENXBIO and BioMarin Pharmaceutical also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may view the grant positively as it indicates the company's commitment to its leadership.

Key Dates